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C1q, the ligand-binding unit of the C1 complex of complement, is a pattern recognition
molecule with the unique ability to sense an amazing variety of targets, including a num-
ber of altered structures from self, such as apoptotic cells.The three-dimensional structure
of its C-terminal globular domain, responsible for its recognition function, has been solved
by X-ray crystallography, revealing a tightly packed heterotrimeric assembly with marked
differences in the surface patterns of the subunits, and yielding insights into its versatile
binding properties. In conjunction with other approaches, this same technique has been
used recently to decipher the mechanisms that allow this domain to interact with various
non-immune self ligands, including molecules known to provide eat-me signals on apop-
totic cells, such as phosphatidylserine and DNA.These investigations provide evidence for
a common binding area for these ligands located in subunit C of the C1q globular domain,
and suggest that ligand recognition through this area down-regulates C1 activation, hence
contributing to the control of the inﬂammatory reaction. The purpose of this article is to
give an overview of these advances which represent a ﬁrst step toward understanding the
recognition mechanisms of C1q and their biological implications.
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INTRODUCTION
Triggering of the classical complement pathway is mediated by
C1, a multimolecular complex resulting from the association of a
recognition subunit, C1q, and a Ca2+-dependent tetramer com-
prising two copies of two serine proteases, C1r, and C1s (Cooper,
1985; Gaboriaud et al., 2004). C1q is a 460-kDa hexameric protein
assembled from six heterotrimeric collagen-like ﬁbers, each being
prolonged by a C-terminal globular domain which mediates the
recognition function of C1 (Gaboriaud et al., 2003, 2004; Kishore
et al., 2004). A major characteristic of this domain lies in its ability
to sense and engage an amazing variety of ligands (Cooper, 1985;
Kishore et al., 2004). Thus,C1q is classically known for its ability to
bind IgG- and IgM-containing immune complexes. In addition, it
recognizes the lectin SIGN-R1, C-reactive protein, and other pen-
traxins bound to pathogens and other surfaces, as well as various
molecular motifs on several Gram-negative bacteria and viruses
(Cooper, 1985; Szalai et al., 1999; Thielens et al., 2002; Kishore
et al., 2004; Kang et al., 2006). In most cases, recognition of these
non-self ligands by C1q triggers activation of the classical comple-
ment pathway, thereby contributing to their elimination through
enhanced phagocytosis, lysis, and inﬂammation.
This traditional view of the biological role of C1q should be
reconsidered in light of recent studies providing evidence that
C1q has the ability to sense many altered structures from self,
including the pathological form of the prion protein (Klein et al.,
2001; Erlich et al., 2010), β-amyloid ﬁbrils (Tacnet-Delorme et al.,
2001),modiﬁed forms of low-density lipoprotein (Biro et al., 2007,
2010), and apoptotic cells (Taylor et al., 2000; Navratil et al.,
2001). Recognition by C1q triggers efﬁcient clearance of apop-
totic cells by phagocytes, but in this case lysis and inﬂammation are
both inhibited, thus contributing to the maintenance of immune
tolerance (Nauta et al., 2004; Fraser et al., 2009). Recent inves-
tigations on the C1q targets at the apoptotic cell surface have
revealed that three molecules known to provide “eat-me” signals,
phosphatidylserine, DNA, and calreticulin, are recognized by C1q,
suggesting a multiligand-binding process (Païdassi et al., 2008a,b,
2011).
The three-dimensional (3-D) structure of the heterotrimeric
globular domain of C1q, responsible for the recognition func-
tion of this protein, has been solved by X-ray crystallography,
giving insights into its versatile binding properties (Gaboriaud
et al., 2003). The same technique, as well as other approaches, have
been recently applied to decipher the interaction of this domain
with various non-immune self ligands, including molecules act-
ing as eat-me signals on apoptotic cells, providing evidence for
a common binding area (Païdassi et al., 2008a; Garlatti et al.,
2010). The purpose of this article is to give an overview of these
advances which shed light on the recognition of self ligands by
C1q and reveal possible implications in the regulation of C1
activation.
ARCHITECTURE OF THE HUMAN C1q GLOBULAR DOMAIN
The 3-D structure of the C-terminal globular domain of human
C1q, obtained after digestion of the collagenous moiety of the
protein with collagenase, has been solved by X-ray crystallogra-
phy to a resolution of 1.9 Å (Gaboriaud et al., 2003). The structure
revealed a globular, almost spherical heterotrimeric assembly,with
a diameter of about 50 Å, the N- and C-termini of each sub-
unit emerging at the base of the trimer, in close vicinity to one
another (Figures 1A,B). A major information from the structure
www.frontiersin.org January 2012 | Volume 2 | Article 92 | 1
Gaboriaud et al. The human C1q globular domain
FIGURE 1 | Structure of the C1q globular domain. (A)Top view and
(B) side view of the heterotrimeric assembly. Subunits A, B, and C are
shown in blue, green, and red, respectively. β-strands are labeled
according to the tumor necrosis factor nomenclature, and the Ca2+ ion
is represented as a golden sphere. N and C indicate the N- and
C-terminal ends of each gC1q subunit. (C) Side view of the
three-dimensional C1q model derived from the structure of the globular
domain. The N-linked oligosaccharide attached to each globular domain
is represented in yellow. (D) Structure of the gC1q subunits. Subunits
A, B, and C are superimposed. Only the free cysteine and disulﬁde
bond of subunit C are displayed for clarity. (Modiﬁed from Gaboriaud
et al., 2003, 2004).
was that the gC1q subunits are arranged clockwise in the order
A, B, C when the assembly is viewed from the top, this indica-
tion enabling us to derive a 3-D model of the collagen-like triple
helix of C1q, and thereby to reconstruct the whole C1q mole-
cule (Gaboriaud et al., 2003, 2004). In the resulting C1q model
(Figure 1C), the B subunit of each globular domain lies on the
outer part of the molecule, whereas A and C are positioned inside.
As discussed later, it is very likely that this particular conﬁgura-
tion has direct implications in terms of ligand recognition and C1
activation.
The three subunits each exhibit a 10-stranded β sandwich fold
with a jelly roll topology homologous to the one described ini-
tially for tumor necrosis factor (Eck and Sprang, 1989; Jones et al.,
1989) and subsequently for members of the gC1q family (Shapiro
and Scherer, 1998; Bogin et al., 2002; Kvansakul et al., 2002), con-
sisting of two ﬁve-stranded β-sheets (A′, A, H, C, F and B′, B,
G, D, E), each made of anti-parallel strands (Figure 1D). Com-
parison of the three subunits indicates strong conservation of
the β-strands and signiﬁcant variability in the loops connecting
them, a characteristic that also applies to other gC1q domains.
In addition to a free cysteine conserved in all gC1q domains,
which is essentially buried in the structure, each subunit of human
C1q contains two other cysteines engaged in a disulﬁde bond
(Figure 1D).
Assembly of theC1q heterotrimer involves a tight association of
the subunits, as shown by a total buried surface of 5490 Å2 equally
contributed by each subunit, this value being signiﬁcantly less,
however, than those in collagens VIII and X (Bogin et al., 2002).
Trimerization involves a central interface as well as lateral interac-
tions which in both cases are hydrophobic at the base of the trimer
and become more polar when going to the apex. This results in
the formation of a discontinuous central channel which is closed
at both extremities. Interestingly, despite its heterotrimeric struc-
ture, the C1q globular domain assembles in the same way as its
homotrimeric counterparts in ACRP30 and collagens VIII and X.
Nevertheless, attempts to assemble gC1q subunits as homotrimers
in silico were found to result in severe steric clashes, particularly at
the level of lateral interactions, thus providing a structural basis for
their natural propensity to associate only as heterotrimers (Gabo-
riaud et al., 2003). The structure of the C1q globular domain also
reveals the presence of a Ca2+ ion bound at the top of the assem-
bly (Figures 1A,B). The binding site is asymmetrical relative to
the trimer, considering that Ca2+ is coordinated by oxygen lig-
ands contributed by subunits A and B, but is not connected to
subunit C. In contrast to the buried Ca2+ cluster observed in col-
lagen X (Bogin et al., 2002), the single Ca2+ ion of C1q is exposed
to the solvent and deﬁnes the upper end of the central channel.
In addition to contributing to the stability of the heterotrimeric
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assembly, the Ca2+ ion may have a functional role. Thus, the loss
of Ca2+ has been postulated to modify the direction of the electric
moment of the C1q globular domain and thereby to inﬂuence the
recognition of immune targets such as C-reactive protein and IgG
(Roumenina et al., 2005). The fact that the Ca2+ ion is accessible
to the solvent also opens the possibility of a direct implication in
the recognition of certain charged targets (Gaboriaud et al., 2003).
THE HETEROTRIMERIC STRUCTURE OF THE C1q GLOBULAR
DOMAIN AS THE KEY TO ITS BINDING VERSATILITY
A striking feature of the structure of the C1q globular domain
lies in the fact that the three subunits exhibit marked differ-
ences in their surface patterns, with respect to both charged and
hydrophobic residues (Figure 2). Thus, subunit A mainly shows
a combination of arginine and acidic residues scattered on its
surface (Figure 2A). Subunit C also shows a combination of
basic and acidic residues spread over the surface (Figure 2C). In
contrast, positively charged residues are predominant on the sur-
face of module B, with in particular a cluster of three arginines
ArgB101, ArgB114, and ArgB129. The latter two residues, which
have been proposed to be involved in the interaction with IgG
(Marqués et al., 1993), markedly protrude outside the structure
(Figure 2B). Several hydrophobic residues are exposed to the
solvent on the external face of each subunit, the most strik-
ing example being the IleB103, ValB105, ProB106 cluster lying
over the ArgB101, ArgB114, ArgB129 triad (Figure 2B). In con-
trast, the only accessible aromatic residues (TyrC155, TrpC190)
are found on the equatorial area of subunit C (Figure 2C). The
top of the heterotrimer (Figure 2D) shows a predominance of
positive charges mainly contributed by lysine residues. In each
subunit, several hydrophobic patches and aromatic residues are
also exposed.
The heterotrimeric structure of the C1q globular domain is
very likely a major determinant of its versatile recognition prop-
erties. Thus, because they display quite different surface pat-
terns in terms of charged and hydrophobic residues, the three
subunits are expected to mediate different individual binding
properties. In addition, considering the tightly packed struc-
ture of the domain, it appears likely that recognition of cer-
tain ligands will involve residues contributed by several sub-
units, thereby considerably enlarging the spectrum of the C1q
targets. This assumption appears consistent with the observa-
tion that many C1q ligands have been found to interact in a
signiﬁcant way with different subunits of its globular domain
(Kishore et al., 2003). As discussed later, the diversity of the
recognition modes of C1q is well illustrated by the models
proposed for C-reactive protein and IgG1, where binding is
thought to involve the apex of the C1q globular domain, and
the equatorial region of subunit B, respectively (Gaboriaud et al.,
2003).
FIGURE 2 | Surface properties of the C1q globular domain.
(A–C) Side views of the heterotrimer seen from subunits A, B, and
C, respectively. (D)Top view of the heterotrimer. The side chains of
Arg, Lys, His, Asp, and Glu residues are shown in deep blue, light
blue, green, red, and magenta, respectively. Hydrophobic residues
are shown in yellow, and aromatic ones are in orange. The lines in
(D) indicate the approximate subunit boundaries. (From Gaboriaud
et al., 2003).
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C1q RECOGNIZES MULTIPLE LIGANDS AT THE APOPTOTIC
CELL SURFACE
Recent investigations on the targets recognized by C1q at the
apoptotic cell surface have allowed us to identify several ligands
(Païdassi et al., 2008a,b, 2011). In all cases, theC1qmoiety respon-
sible for binding has been shown to be the globular domain.
Phosphatidylserine is currently one of the best documented
recognition signal required for apoptotic cell clearance. Its tether-
ing is mediated directly by phagocyte receptors, with or without
the help of soluble bridging molecules (Savill et al., 2002).We have
recently shown that C1q is one of the molecules that bridge phos-
phatidylserine exposed at the surface of early apoptotic cells to the
phagocyte (Païdassi et al., 2008a). The interaction is mediated by
its globular domain, which recognizes the phosphoserine moiety
of phosphatidylserine. Annexin V, which binds avidly to phos-
phatidylserine, inhibits the interaction, and C1q and its globular
domain both co-localize with phosphatidylserine on the apoptotic
cell surface. Surface plasmon resonance analysis of the interac-
tion between theC1q globular domain and phosphatidylserine has
revealed high-afﬁnity (Figure 3A) and the phosphoserine binding
site onC1qhas been identiﬁedbyX-ray crystallography (Figure 4).
Nuclear splitting and DNA fragmentation are well-established
features of apoptosis, and the generation of auto-antibodies
directed against chromatin components is a characteristic of
autoimmune diseases such as systemic lupus erythematosus and
rheumatoid arthritis (Shoenfeld et al., 1987). It was recently
demonstrated that nucleic acids are rapidly exposed during apop-
tosis and provide ligands for C1q binding (Elward et al., 2005). In
an attempt to characterizeC1q binding toDNA,we have shown for
the ﬁrst time that the globular region of C1q displays a lectin-like
activity that contributes to DNA binding (Païdassi et al., 2008b).
This observation is consistent with the observation that treatment
of apoptotic cells with DNase decreases signiﬁcantly binding to
C1q. Studies at themolecular level have demonstrated that theC1q
globular domain binds DNA through its pentose moiety, and that
deoxy-d-ribose inhibits formation of complexes between DNA
and the C1q globular domain (Figure 3B). The structure of the
deoxy-d-ribose binding site on the C1q globular domain has been
deciphered at high resolution by X-ray crystallography.
Calreticulin was ﬁrst identiﬁed as a receptor for the collagenous
moiety of C1q and the collectins at the surface of phagocytes.How-
ever, based on more recent studies, it is now widely accepted that
calreticulin is a major recognition signal at the apoptotic cell sur-
face, acting as an“eat-me” signal in the uptake of apoptotic cells by
macrophages (Gardai et al., 2006; Obeid et al., 2007). This latter
ﬁnding evokes a double play for this protein, as both a phago-
cyte receptor and an “eat-me” signal on the apoptotic cell surface,
with the help of the bridging molecule C1q. In support of this
hypothesis, we have recently demonstrated that the C1q globular
domain, responsible for C1q binding to apoptotic cells, binds cal-
reticulin with high-afﬁnity and co-localizes with this protein on
the apoptotic cell surface (Figure 3C; Païdassi et al., 2011).
A COMMON BINDING AREA FOR NON-IMMUNE SELF
LIGANDS
To decipher the recognition properties of the C1q globular
domain, its X-ray structure has been solved in the presence of
FIGURE 3 | C1q binding to apoptotic cell ligands. (A) Surface plasmon
resonance analysis of the binding of the C1q globular domain to
immobilized phosphatidylserine. The concentrations of the C1q globular
domain are indicated. (B) Electrophoretic mobility shift assay showing that
complex formation between DNA and the C1q globular domain is partly
inhibited by 100mM deoxy-D-ribose. Mannose was used as a negative
control. DNA molecular weight markers are shown on the left. (C) Early
apoptotic HeLa cells were submitted to a double-immunoﬂuorescence
labeling for the C1q globular domain (C1q GR, green) and calreticulin (CRT,
red) followed by confocal laser microscopy detection. Nuclei were labeled
with Hoechst (blue). The white bow indicates areas where the C1q globular
domain co-localizes with calreticulin. (From Païdassi et al., 2008a,b, 2011).
three different small ligands corresponding to molecular deter-
minants recognized by C1q in larger target molecules from self:
(i) phosphoserine, the motif recognized in phosphatidylserine,
(ii) deoxy-d-ribose, a speciﬁc determinant of DNA, and (iii)
two repetitive units of heparan sulfate (Païdassi et al., 2008a;
Garlatti et al., 2010). The three structures were solved using
crystal soaking because attempts to generate co-crystals of the
C1q globular domain in complex with a ligand were unsuccess-
ful. The soaking technique introduces space constraints, and is
more favorable to small ligands. The smallest ligand tested, deoxy-
d-ribose, was observed at the highest resolution (1.25 Å) in a
convincing binding site located in subunit C of the C1q globular
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FIGURE 4 | Location of three non-immune self ligand-binding sites in
the C1q globular domain. (A) Overall view of the C1q globular domain
indicating the relative positioning of the binding sites for heparan sulfate
(HS), deoxy-D-ribose (dR), and phosphoserine (PS). (B–D) Detailed views of
the binding sites for deoxy-D-ribose, heparan sulfate, and phosphoserine,
respectively. Residues of the C subunit involved in the interaction are
shown. In (C), the ligand portion displayed in sticks corresponds to the
major interpretable extra electron-density. In (D), a double conformation
was used to interpret the extra-density corresponding to phosphoserine.
(Modiﬁed from Garlatti et al., 2010 and Païdassi et al., 2008a).
domain (Garlatti et al., 2010). It is accommodated in a small
pocket lying between ArgC98 and ArgC111 (Figure 4B). Two of
its hydroxyl groups are stabilized by direct and water-mediated
polar interactions with AsnC113, ArgC111, and ArgC118. The
interaction is clearly speciﬁc to deoxy-d-ribose, since no ligand
ﬁxation could be detected when the same protocol was applied
using d-ribose. Indeed, the additional hydroxyl group present in
ribose would clash sterically with AsnC113 in the observed con-
ﬁguration, providing a structural basis for the strict speciﬁcity
of C1q toward deoxy-d-ribose. The other two ligands investi-
gated, phosphoserine and heparan sulfate, are both negatively
charged, and interact approximately in the same area of the C
subunit of the C1q globular domain (Figure 4A), although they
differ in their precise interaction modes (Païdassi et al., 2008a;
Garlatti et al., 2010). Thus, heparan sulfate is interacting with
TyrC155, TrpC190, and LysC129 (Figure 4C), whereas phos-
phoserine binds ArgC111, SerC126, and ThrC127 (Figure 4D).
The sulfate/phosphate binding propensity of ArgC98, ArgC111,
TyrC155, and TrpC190 suggests that this area has the ability to
bind larger polyanionic molecules. If this hypothesis is correct,
then the larger polyanionic molecules DNA and heparin are
expected to compete with each other because of the close prox-
imity of their binding sites. This hypothesis has been tested
using competition experiments, providing evidence that, indeed,
DNA and heparan sulfate fragments each inhibit in a dose-
dependent manner C1q binding to a HS-coated surface, in com-
plete agreementwithX-ray crystallography analyses (Garlatti et al.,
2010).
THE LOCATION OF A LIGAND-BINDING SITE ON THE C1q
GLOBULAR DOMAIN CORRELATES WITH ITS C1 ACTIVATION
POTENTIAL
According to the C1q model derived from the X-ray structure of
its globular domain (Figure 1C), the binding sites for phospho-
serine, deoxy-d-ribose, and heparan sulfate, all located in subunit
C, would be positioned on the inner face of the C1q cone, and
oriented toward the target (Figures 4A and 5A). In contrast, the
IgG binding site has been proposed to lie on the equatorial region
of subunit B, on the outer part of the C1q molecule (Gaboriaud
et al., 2003; Garlatti et al., 2010). In light of our current knowl-
edge of the structure and activation mechanism of the C1 complex
(Budayova-Spano et al., 2002; Gaboriaud et al., 2003, 2004; Bally
et al., 2009; Brier et al., 2010), these locations have direct functional
implications in terms of C1 activation. Thus, the X-ray structure
of the zymogen C1r catalytic domain has led to the conclusion
that an outward movement of the C1q stems is necessary to dis-
rupt the resting head-to-tail dimeric structure of C1r and thereby
trigger C1 activation (Figures 5B–D). If this assumption is cor-
rect, any ligand recognized through the outer part of the C1q
globular domain, as proposed for IgG (Figure 5A), is expected to
trigger efﬁcient C1 activation (Figure 5F). Conversely, given the
inner positioning of their interaction sites, binding of ligands such
as phosphoserine, deoxy-d-ribose, and heparan sulfate would be
unable to generate the appropriate outward movement of the C1q
stems, particularly if these ligands are clustered in dense surface
patches, thus preventing or restraining activation of the C1 com-
plex. In full agreement with this hypothesis, it has been shown that
immune complexes trigger efﬁcient activation of C1 in the pres-
ence of C1 inhibitor, in contrast to DNA and heparin (Figure 5E;
Ziccardi, 1982; Garlatti et al., 2010).
CONCLUSION
Uncontrolled activation of the classical complement pathway is
involved in many inﬂammatory pathologies. Conversely,C1q deﬁ-
ciency is associated with major defaults in the uptake of apoptotic
cells and correlates with autoimmune diseases such as systemic
lupus erythematosus and glomerulonephritis, emphasizing the
crucial role of C1q in the maintenance of immune tolerance
(Botto and Walport, 2002). Whereas heparan sulfate and other
sulfated molecules are known to inhibit complement activation,
DNA, and phosphatidylserine are both eat-me signals involved in
the removal of apoptotic cells by C1q. It is tempting to hypothe-
size that, because the binding sites for these ligands are all located
within the same area of theC1q globular domain,on the inner edge
of the C1q cone, their recognition by C1q only generates low C1
activation, hence contributing to the control of the inﬂammatory
reaction, in addition to complement regulators (Zipfel and Skerka,
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FIGURE 5 | Implications on C1 activation of the location of
ligand-binding sites in the C1q globular domain. (A) Location of the
ligand-binding sites according to the current version of the C1q model.
Nisl: non-immune self ligands binding area as described in Figure 4; IC:
proposed binding sites for IgG-containing immune complexes. (B) Dimeric
structure of the C1r catalytic domain in its “resting state.” In this
conﬁguration, a distance of 90Å is observed between the catalytic site
(C1r_cat) of one subunit and the activation site (colored star) to be cleaved
in the other subunit. Such a distance prevents unwanted spontaneous C1r
autoactivation, which requires transient disruption of the dimer. (C,D)
Bottom and side views, respectively, of the current C1 model (Bally et al.,
2009; Brier et al., 2010). In (C) white stars show the approximate positions
of the C1r activation sites. (E) C1 activation by IgG-containing immune
complexes, heparin and DNA. (F) Schematic interpretation of (E).
According to our hypothesis, a strong outward movement of the C1q
stems (red arrows) induced by binding to immune complexes is expected
to disrupt the C1r catalytic dimer and thereby induce C1 activation. In
contrast, binding to non-immune self ligands would generate little or no
activation (green arrows). (Modiﬁed from Budayova-Spano et al., 2002 and
Garlatti et al., 2010).
2009). Recently, another molecule from self, heme, was shown to
bind C1q and inhibit C1 activation by immune complexes and
C-reactive protein (Roumenina et al., 2011). Interestingly, one of
the two heme binding sites postulated by these authors is located
in subunit C of the C1q globular domain, in the vicinity of the
sites identiﬁed for DNA, phosphatidylserine, and heparan sulfate,
suggesting that heme-mediated inhibition of C1 activation could
involve a similar mechanism.
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It is clear, however, that this scheme does not apply to all known
non-immune C1q self ligands. Thus, whereas the oxidized form
of low-density lipoprotein (ox-LDL) does not trigger C1 activa-
tion despite its ability to bind C1q with high-afﬁnity (Biro et al.,
2007), the enzymatically modiﬁed species (E-LDL) is a potent C1
activator (Biro et al., 2007, 2010). In the same way, cardiolipin,
β-amyloid ﬁbrils, as well as different forms of the prion protein
have been shown to bind C1q and activate C1 to various extents
(Peitsch et al., 1988; Tacnet-Delorme et al., 2001;Dumestre-Pérard
et al., 2007; Sim et al., 2007; Sjöberg et al., 2008). Further investi-
gations at the molecular level will be necessary to generate a more
detailed map of the ligand-binding sites of C1q and uncover all the
secrets of this unique sensor molecule. Such advances would have
important potential therapeutic applications, considering that lig-
and recognition by C1q may elicit both beneﬁcial and deleterious
effects, as exempliﬁed in neurodegenerative diseases where both
types of effects have been reported (van Beek et al., 2003; Veerhuis
et al., 2011). Ideally, the aim would be to modulate the classi-
cal complement pathway by preventing or limiting its noxious
effects while preserving its protective role. In the long term, this
goal should be achievable through the design of inhibitory mol-
ecules able to speciﬁcally target the strong C1-activating binding
sites located on the outer part of the C1q globular domain, while
preserving the functionality of the inner binding area allowing
recognition and efﬁcient clearance of altered self ligands.
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